FibroGen (FGEN) Competitors

FibroGen (NASDAQ:FGEN) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Is FGEN or NKTX more profitable?

Nkarta has a net margin of 0.00% compared to FibroGen's net margin of -67.66%. FibroGen's return on equity of 0.00% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FibroGen	-67.66%	N/A	-36.17%
Nkarta	N/A	-27.13%	-21.67%

Which has stronger earnings and valuation, FGEN or NKTX?

Nkarta has lower revenue, but higher earnings than FibroGen. Nkarta is trading at a lower price-to-earnings ratio than FibroGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroGen	$29.62M	1.01	-$284.23M	-$0.48	-0.62
Nkarta	N/A	N/A	-$117.50M	-$1.66	-1.03

Which has more risk & volatility, FGEN or NKTX?

FibroGen has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Do institutionals and insiders hold more shares of FGEN or NKTX?

72.7% of FibroGen shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 2.0% of FibroGen shares are held by insiders. Comparatively, 8.7% of Nkarta shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Does the MarketBeat Community believe in FGEN or NKTX?

FibroGen received 282 more outperform votes than Nkarta when rated by MarketBeat users. However, 78.05% of users gave Nkarta an outperform vote while only 59.25% of users gave FibroGen an outperform vote.

Company	Underperform	Outperform
FibroGen	Outperform Votes 346 59.25%	Underperform Votes 238 40.75%
Nkarta	Outperform Votes 64 78.05%	Underperform Votes 18 21.95%

Do analysts recommend FGEN or NKTX?

FibroGen currently has a consensus target price of $10.00, suggesting a potential upside of 3,276.10%. Nkarta has a consensus target price of $14.86, suggesting a potential upside of 768.84%. Given FibroGen's higher possible upside, equities research analysts plainly believe FibroGen is more favorable than Nkarta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroGen	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Nkarta	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25

Does the media refer more to FGEN or NKTX?

In the previous week, Nkarta had 4 more articles in the media than FibroGen. MarketBeat recorded 5 mentions for Nkarta and 1 mentions for FibroGen. FibroGen's average media sentiment score of 1.87 beat Nkarta's score of 0.71 indicating that FibroGen is being referred to more favorably in the media.

Company	Overall Sentiment
FibroGen	Very Positive
Nkarta	Positive

Summary

Nkarta beats FibroGen on 10 of the 18 factors compared between the two stocks.